- 1 September 2022 - 

Behind the scenes of the Metastatic breast cancer GPS – AURORA : what are funds used for?   

Conducting international breast cancer research costs a lot of money. These high financial needs relate to the number of countries, research groups, and hospitals involved; the number of patients who need to be screened in order to select the ones who can be included; the state-of-the-art technologies used; the types of biospecimens collected, stored, and analyzed; and, finally, the great variety of activities carried out to ensure that the study meets all ethical, quality, and legal requirements.

BIG’s Metastatic breast cancer GPS – AURORA  program, which aims to improve our understanding of this disease, to identify genetic breakdowns, and to map the routes that cancer cells take to invade other organs, will be carried out over 18 years (2013-2031). This includes the original first phase of the program with 1,150 patients, and a second phase with 262 patients who have particularly challenging types of metastatic breast cancer.  

Calculating the budget of a study that runs for many years is very difficult. The cost of technologies and services change, and inflation and other factors can be quite unpredictable. It is now estimated that the total cost for AURORA will amount to +/- 40 million euros. 32 million euros have already been secured through the generous support of grants, partnerships, and individual donations, but there remain 3.5 million euros to be raised, about 350,000 euros per year for the next 10 years.